Ablation Cuts Risk of Recurrent Stroke in Patients With A-Fib

This article originally appeared here.
Share this content:
Ablation Cuts Risk of Recurrent Stroke in Patients With A-Fib
Ablation Cuts Risk of Recurrent Stroke in Patients With A-Fib

TUESDAY, Nov. 28, 2017 (HealthDay News) -- For patients with atrial fibrillation (AF) and prior cerebrovascular accident (CVA), ablation is associated with reduced risk of recurrent stroke, according to a study published online Nov. 13 in the Journal of Cardiovascular Electrophysiology.

Thomas Jared Bunch, M.D., from the Intermountain Medical Center in Murray, Utah, and colleagues examined outcomes for AF ablation patients receiving their first ablation (139 patients), AF patients who did not receive ablation (416 patients), and CVA patients without clinical AF (416 patients). Patients had prior CVA, as determined by medical chart review, and five years of follow-up.

The researchers found that patients with AF ablation had higher rates of hypertension and heart failure (P < 0.0001), but the prevalence of diabetes was similar between the groups (P = 0.5). The AF, no ablation group had higher five-year risk of CVA (hazard ratio, 2.26; P < 0.0001) and death (hazard ratio, 2.43; P < 0.0001) than the ablated group. The five-year risk for CVA (hazard ratio, 0.82; P = 0.39) and death (hazard ratio, 0.92; P = 0.70) did not differ significantly when comparing AF patients with ablation to patients without AF; however, the risk of heart failure was increased (hazard ratio, 3.08; P = 0.001).

"In patients with AF and a prior CVA, patients undergoing ablation have lower rates of recurrent stroke compared to AF patients not ablated," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical technology industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A&#43;AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »